AIM
LCTX icon

Acrospire Investment Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Acrospire Investment Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-4,007
Closed -$12K – 2366
2017
Q1 		$12K Sell
4,007
-2,742
-41% -$7.79K 0.01% 1826
2016
Q4 		$21K Buy
+6,749
New +$20.7K 0.01% 1743

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return
DWM
Destination Wealth Management Walnut Creek, California $3.85B AUM 13% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Acrospire Investment Management's LCTX Position: Q2 2017 in Review

Acrospire Investment Management sold out of Lineage Cell Therapeutics (LCTX) in Q2 2017, closing a stake of 4,007 shares — an estimated $12K sold.

Acrospire Investment Management first reported a position in LCTX in Q4 2016 and held it in 2 quarters. The position peaked at $21K in Q4 2016. 109 funds tracked by Wall St. Rank hold LCTX as of Q2 2017.

  • Acrospire Investment Management reported no remaining Lineage Cell Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 4,007 Lineage Cell Therapeutics shares in Q2 2017, an estimated $12K.
  • Acrospire Investment Management first reported a position in Lineage Cell Therapeutics in Q4 2016 and held it in 2 quarters.
  • Acrospire Investment Management's Lineage Cell Therapeutics position peaked at $21K in Q4 2016.
  • 109 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2017.

Based on Acrospire Investment Management's 13F filing for Q2 2017, filed 11 Aug 2017.